Development of Test System for Detection of V617F Mutation of JAK2 Gene in Patients with Chronic Myeloproliferative Disorders
DOI:
https://doi.org/10.15407/scin5.06.059Keywords:
diagnostics, JAK2, myeloproliferative disorders, PCR, V617FAbstract
V617F mutation of jak2 gene is an important diagnostic criterion for chronic myeloproliferative disorders. The testsystem for detection of the mutation by using the method of reverse transcription polymerase chain reaction and direct sequencing of PCR products was proposed.
References
Dameshek W. Some speculations on the myeloproliferative syndromes. Blood. 1951. V. 6. P. 372-375.
Vardiman J.W., Harris N.L., Brunning R.D. The World Health Organization (WHO) classification of the myeloid neo plasms. Blood. 2002. V. 100. P. 2292-2302.
https://doi.org/10.1182/blood-2002-04-1199
Baxter E.J., Scott L.M., Campbell P.J. et al. Acquired mutation of the tyrosine kinase JAK2 in human myeloproliferative disorders. Lancet. 2005. V. 365, N 9464. P. 1054-1061.
https://doi.org/10.1016/S0140-6736(05)74230-6
Kralovics R., Passamonti F., Buser A.S. et al. A gain-of-function mutation of JAK2 in myeloproliferative disorders. N Engl J Med. 2005. V. 352, N 17. P. 1779-1790.
https://doi.org/10.1056/NEJMoa051113
Levine R.L., Wadleigh M., Cools J. et al. Activating mutation in the tyrosine kinase JAK2 in polycythemia vera, essential thrombocythemia, and myeloid metaplasia with myelofibrosis. Cancer Cell. 2005. V. 7, N 4. P. 387-397.
https://doi.org/10.1016/j.ccr.2005.03.023
Zhao R., Xing S., Li Z. et al. Identification of an acquired JAK2 mutation in polycythemia vera. J Biol Chem. 2005. V. 280, N 24. P. 22788-22792.
https://doi.org/10.1074/jbc.C500138200
James C., Ugo V., Le Couedic J.P. et al. A unique clonal JAK2 mutation leading to constitutive signalling causes polycythaemia vera. Nature. 2005. V. 434. P. 1144-1148.
https://doi.org/10.1038/nature03546
Scott L.M., Tong W., Levine R.L. JAK2 exon 12 mutations in polycythemia vera and idiopathic erythrocytosis. N Engl J Med. 2007. V. 356, N 5. P. 459-468.
https://doi.org/10.1056/NEJMoa065202
Tefferi A., Vardiman J.W. Classification and diagnosis of myeloproliferative neoplasms: The 2008 World Health Organization criteria and point-of-care diagnostic algorithms. Leukemia. 2008. V. 22. P. 14-22.
https://doi.org/10.1038/sj.leu.2404955
Spivak J.L., Silver R.T. The revised World Health Organization diagnostic criteria for polycythemia vera, essential thrombocytosis, and primary myelofibrosis: an alternative proposal. Blood. 2008. V. 112, N 2. P. 231-239.
https://doi.org/10.1182/blood-2007-12-128454
Chomczynski P., Sacchi N. Single-step method of RNA iso lation by acid guanidinum thiocyanate-phenol-chloroform extraction. Analyt. Biochem. 1987. V. 162. P. 156-159.
https://doi.org/10.1016/0003-2697(87)90021-2
Telegejev G.D., Dybkov M.V., Bozhko M.V. ta in. Monitoryng hronichnogo mijelolejkozu za dopomogoju molekuljarno-biologichnyh metodiv (metodychni rekomendacii'). Respublikans'kyj centr naukovo-medychnoi' informacii'. Kyi'v, 1997 [in Ukrainian].
Hussein K., Bock O., Seegers A., Flasshove M. et al. Myelofibrosis evolving during imatinib treatment of a chronic myeloproliferative disease with coexisting BCR-ABL translocation and JAK2V617F mutation. Blood. 2007. V. 109, N 9. P. 4106-4107.
https://doi.org/10.1182/blood-2006-12-061135
Bocchia M., Vannucchi A.M., Gozzetti A. et al. Insights into JAK2–V617F mutation in CML. Lancet Oncol. 2007. V. 8. P. 864-866.
